TBPH
Closed
Theravance Biopharma Inc
10.91
-0.12 (-1.09%)
Last Update: 01 Jul 2025 23:12:00
Yesterday: 11.03
Day's Range: 10.87 - 11.115
Send
sign up or login to leave a comment!
When Written:
11.38
Theravance Biopharma, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule medicines for the treatment of serious diseases. The company was founded in 2014 and is headquartered in South San Francisco, California.
Theravance Biopharma's pipeline includes treatments for respiratory diseases, gastrointestinal disorders, and central nervous system disorders. The company's lead product is called Vibativ, which is an antibiotic used to treat serious infections caused by gram-positive bacteria.
Theravance Biopharma is also developing a drug called TD-1473 for the treatment of inflammatory bowel disease, as well as a drug called TD-9855 for the treatment of neurogenic orthostatic hypotension.
The company has partnerships with several other pharmaceutical companies, including GlaxoSmithKline and Mylan, to develop and commercialize its products.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Theravance Biopharma's pipeline includes treatments for respiratory diseases, gastrointestinal disorders, and central nervous system disorders. The company's lead product is called Vibativ, which is an antibiotic used to treat serious infections caused by gram-positive bacteria.
Theravance Biopharma is also developing a drug called TD-1473 for the treatment of inflammatory bowel disease, as well as a drug called TD-9855 for the treatment of neurogenic orthostatic hypotension.
The company has partnerships with several other pharmaceutical companies, including GlaxoSmithKline and Mylan, to develop and commercialize its products.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








